Curida

Curida is a well-established, Norway-based CDMO with over 50 years of collective GMP expertise, founded in 1987. It provides specialized contract manufacturing services across two core sectors: Biologics (including monoclonal antibodies and diagnostics) and Liquid Formulations (focusing on nasal sprays, ophthalmics, and pharmacy compounds). With GMP-certified facilities in Norway and a team of over 200 employees, the company serves more than 40 global partners, offering end-to-end support from process development to commercial supply. Its technology platform is built around sterile fill-finish capabilities, particularly Blow-Fill-Seal, positioning it as a niche player in complex liquid and biologic drug delivery.

Specialized aseptic fill-finish platform utilizing Blow-Fill-Seal (BFS), nasal spray manufacturing, liquid bottle systems, and flexible dose formats for sterile liquid and biologic drug products.

Curida competes in the global CDMO market against large players like Lonza, Catalent, and Recipharm, as well as niche specialists in fill-finish and drug delivery. Its differentiation lies in its deep expertise in Blow-Fill-Seal technology, nasal spray manufacturing, and its focused European presence.